SUPPORTING INFECTIOUS DISEASE RESEARCH

Plasmodium falciparum, Strain 7G8

Catalog No. MRA-926

This reagent is the tangible property of the U.S. Government.

Product Description:

Plasmodium falciparum (P. falciparum), strain 7G8 was cloned from the IMTM22 strain by limiting dilution. The original IMTM22 strain was isolated from a 12-year-old male near Manaus, Brazil in 1980. MRA-926 was produced by cultivation of BEI Resources MR-MRA-926 lot 58422570 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 μ g/mL hypoxanthine and 2.5 μ g/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 15 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

Lot: 70033465

Manufacturing Date: 02APR2020

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy ¹	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (in vitro) ¹		
Half-maximal Inhibitory Concentration (IC50) by SYBR		
green l [®] drug sensitivity assay ²		
Chloroquine	Report results	52.1 ± 1.2 nM
Artemisinin	Report results	4.7 ± 0.3 nM
Quinine	Report results	83.1 ± 5.7 nM
Cycloguanil	Report results	844.8 ± 38.9 nM
Pyrimethamine	Report results	45680 ± 1052 nM
Sulfadoxine	Report results	336000 ± 23229 nM
Genotypic Analysis ¹		
Sequencing of Merozoite Surface Protein 2 (MSP2)	\geq 99% sequence identity to	99.8% sequence identity to
gene (~ 710 base pairs)	P. falciparum, strain 7G8	P. falciparum, strain 7G8
	(GenBank: ABGZ02000545)	(GenBank: ABGZ02000545) (Figure 1)
MSD2 DCD emplicen englycia	. 600 000 hass pair emplican	
MSP2 PCR amplicon analysis	~ 600-900 base pair amplicon	~ 900 base pair amplicon
Level of Parasitemia by Giemsa Stain Microscopy		
Pre-freeze (15 days post-infection) ³	Demontracylta	2.40%
Ring-stage parasitemia	Report results	2.46%
Total parasitemia	≥ 2%	4.10%
Post-freeze (4 days post-infection) ¹	Demontración	4.040/
Ring-stage parasitemia	Report results	1.04%
Total parasitemia	≥ 1%	2.61%
Viability (post-freeze; 4 days post-infection) ¹	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation) ¹		
Harpo's HTYE broth, 37°C and 25°C, aerobic ⁴	No growth	No growth
Trypticase soy broth, 37°C and 25°C, aerobic	No growth	No growth
Sabouraud broth, 37°C and 25°C, aerobic	No growth	No growth
DMEM with 10% FBS, 37°C, aerobic	No growth	No growth
Sheep blood agar, 37°C, aerobic	No growth	No growth
Sheep blood agar, 37°C, anaerobic	No growth	No growth
Thioglycollate broth, 37°C, anaerobic	No growth	No growth
Mycoplasma Contamination ¹		
DNA detection by PCR	None detected	None detected
¹ Testing completed on vialed, post-freeze material	·	•

¹Testing completed on vialed, post-freeze material

BEI Resources www.beiresources.org **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

²A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In <u>Methods in Malaria Research Sixth Edition</u>. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <u>https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx.</u>]

³Testing completed on bulk material prior to vialing and freezing

⁴Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-926 MSP2 Sequence

TTAAAAATGA AAGTAAATAT AGCAACACAT TCATAAACAA TGCTTATAAT ATGAGTATAA GGAGAAGTAT GGCAGAAAGT AATCCTTCTA CTGGTGCTGG TGGTAGTGGT AGTGCTGGTG GTAGTGGTGG TGCTGGTGGT AGTGGTAGTG CTGGTGGTAG TGGTAGTGCT GGTGGTAGTG GTAGTGCTGG TTCTGGTGAT GGTAATGGTG CTAATCCTGG TGCAGATGCT GAGAGAAGTC CAAGTACTCC CGCTACTACC ACAACTACCA CAACTACTAA TGATGCAGAA GCATCTACCA GTACCTCTC AGAAAATCCA AATCATAATA ATGCCGAAAC AAATCCAAAA GGTAAAGGAG AAGTTCAAAA ACCAAATCAA GCAAATAAAG AAACTCAAAA TAACTCAAAT GTTCAACAAG ACTCTCAAAC TAAATCAAAT GTTCCACCA CTCAAGATGC AGACACTAAA AGTCCTACTG CACAACCTGA ACAAGCTGAA AATCCTGCTC CAATAGCCGA ACAAACTGAA TCCCCCGAAT TACAATCTGC ACCAGAGAT AAAGGTACAG GACAACATGG ACATATGCAT GGTTCTAGAA ATAATCATCC ACAAAATACT TCTGATAGTC AAAAAGAATG TACCCGATGGT AACAAAGAAA ACTGTGGAGC AGCACCATCC CTCTTAAGTA ACTCTAGTAA TATTTGCTTC A

/Heather Couch/

Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



23 JUL 2020